Jacob Becraft

Jacob Becraft is a co-founder of Strand Therapeutics, a company operating in the biotechnology research sector. Strand Therapeutics programmable mRNA. Based in Cambridge, Massachusetts, United States, Jacob leads the company's strategic vision and day-to-day operations.

Under Jacob's leadership, Strand Therapeutics recently secured $153M in Series B funding on August 7, 2025, backed by investors including Kinnevik. This funding milestone reflects strong investor confidence in both the founding team's execution capabilities and the company's market opportunity.

With fresh capital, Jacob and the team are focused on scaling operations, expanding the product roadmap, and building out a world-class team. The biotechnology research market continues to see significant investment activity, positioning Strand Therapeutics to capitalize on growing demand.For vendors and partners, this represents an ideal window to engage.